NovaBridge Biosciences (NBP) Stock

About NovaBridge Biosciences

NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.

NovaBridge Biosciences is headquartered in US.

NovaBridge Biosciences (NBP) stock trades at $1.40 with a market capitalization of $160.80M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.44, reflecting a net loss over the last twelve months, price-to-book of 0.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.31 and $6.79, and currently trades 79.4% below its 52-week high.

On profitability, NovaBridge Biosciences generates a return on equity (ROE) of -1.45% (negative, reflecting a net loss), return on capital employed of -29.21%.

Official website: www.novabridge.com

NovaBridge Biosciences by the numbers, 2017–2025

Between 2017 and 2025 NovaBridge Biosciences reported revenue of $11.0M rising to $0, a change of -100.0% across 9 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit rose to $-7.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-49.0M.

Borrowings fell from $213.0M to $0, cash on hand is $190.8M, cash from operations was $-21.0M in the latest year, positive in 1 of the last 9.

Return on equity has averaged -198.8% over five years, and was -21.2% in the most recent year.

The share price itself has compounded at —% a year over five years, -2.4% over three, -71.2% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

NovaBridge Biosciences (NBP) — frequently asked questions